BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 829619)

  • 1. [Results of the use of fluphenazine in a depot preparation].
    Marcjan K; Pietruszewska I; Wolak E
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():176-82. PubMed ID: 829619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trial at the guidance center of ixelles of a major neuroleptic drug: anatensol decanoate].
    Berliner J
    Acta Psychiatr Belg; 1974 May; 74(3):305-16. PubMed ID: 4455024
    [No Abstract]   [Full Text] [Related]  

  • 3. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders].
    Ngui PW
    Seishin Shinkeigaku Zasshi; 1983; 85(9):635-9. PubMed ID: 6676769
    [No Abstract]   [Full Text] [Related]  

  • 5. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of schizophrenic psychoses with Lyorodin].
    Schulz HD; Kluge HH; Korda W; Kube B
    Psychiatr Neurol Med Psychol (Leipz); 1977 Jun; 29(6):360-6. PubMed ID: 918199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
    Zhang YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
    Gaby N; Lefkowitz D; Israel JR
    N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparative study of the action of fluphenazine oenanthate and decanoate in chronic psychoses (73 cases)].
    Martin A; Masson JM; Quentin JC; Verrier JP; Jusseaume P
    Ann Med Psychol (Paris); 1972 Dec; 2(5):705-8. PubMed ID: 4576210
    [No Abstract]   [Full Text] [Related]  

  • 14. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term use of high doses of fluphenazine enanthate and fluphenazine decanoate.
    Verhaegen JJ
    Compr Psychiatry; 1975; 16(4):357-62. PubMed ID: 1157479
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The position of the depot-neuroleptics in the therapy of chronic psychoses. Experience with fluphenazine-decanoate].
    Auch W
    Med Welt; 1970 Oct; 21(41):1785-8. PubMed ID: 5471981
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapy with injectable fluphenazines.
    Ayd FJ
    Curr Psychiatr Ther; 1976; 16():177-89. PubMed ID: 991628
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical observations of treatment with Lyorodin-depot (Jenapharm)].
    Pirozynski T; Chiriţă V; Cosmovici N; Offenberg C; Chiriac ME; Marinescu V; Cojocaru M; Berlescu M; Mungiu A
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):501-9. PubMed ID: 2700035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug monitoring at an Australia depot phenothiazine clinic.
    Marriott P; Hiep A
    J Clin Psychiatry; 1978 Mar; 39(3):206-12. PubMed ID: 580271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.